Spark Therapeutics, Inc. drugs

1 result
  • luxturna - voretigene neparvovec - rzyl

    (Voretigene Neparvovec-Rzyl)
    Spark Therapeutics, Inc.
    Luxturna is a gene therapy for patients with biallelic RPE65 mutation-associated retinal dystrophy who have viable retinal cells.